BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $104.00 at The Goldman Sachs Group

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) had its target price lowered by stock analysts at The Goldman Sachs Group from $124.00 to $104.00 in a research report issued on Monday,Benzinga reports. The firm presently has a "buy" rating on the biotechnology company's stock. The Goldman Sachs Group's price objective points to a potential upside of 66.81% from the company's previous close.

Several other research analysts also recently weighed in on the company. StockNews.com upgraded BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Friday, April 25th. Scotiabank raised their target price on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a "sector perform" rating in a research note on Thursday, February 20th. Bank of America boosted their price target on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a "buy" rating in a research note on Thursday, February 20th. Royal Bank of Canada restated a "sector perform" rating and set a $70.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Finally, Wedbush reissued an "outperform" rating and set a $94.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Seven analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $93.45.

BioMarin Pharmaceutical Price Performance

NASDAQ:BMRN traded up $0.32 during trading hours on Monday, hitting $62.35. 214,200 shares of the stock traded hands, compared to its average volume of 1,857,035. The company has a market cap of $11.90 billion, a price-to-earnings ratio of 28.39, a price-to-earnings-growth ratio of 0.61 and a beta of 0.27. BioMarin Pharmaceutical has a 1 year low of $52.93 and a 1 year high of $94.85. The stock has a 50 day moving average price of $65.84 and a 200 day moving average price of $65.71. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The company had revenue of $747.31 million during the quarter, compared to the consensus estimate of $711.05 million. Sell-side analysts forecast that BioMarin Pharmaceutical will post 3.15 EPS for the current fiscal year.

Insider Buying and Selling at BioMarin Pharmaceutical

In other news, CAO Erin Burkhart sold 1,295 shares of the company's stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.52, for a total value of $92,618.40. Following the transaction, the chief accounting officer now directly owns 16,955 shares in the company, valued at approximately $1,212,621.60. This represents a 7.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.85% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Hedge funds have recently added to or reduced their stakes in the stock. Norges Bank purchased a new position in BioMarin Pharmaceutical during the 4th quarter worth $234,645,000. Capital Research Global Investors increased its stake in shares of BioMarin Pharmaceutical by 23.8% during the fourth quarter. Capital Research Global Investors now owns 12,991,772 shares of the biotechnology company's stock valued at $853,944,000 after buying an additional 2,496,817 shares during the period. Soleus Capital Management L.P. bought a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $65,822,000. Dodge & Cox lifted its stake in BioMarin Pharmaceutical by 6.1% in the fourth quarter. Dodge & Cox now owns 14,746,235 shares of the biotechnology company's stock worth $969,270,000 after acquiring an additional 847,917 shares during the period. Finally, AQR Capital Management LLC grew its holdings in BioMarin Pharmaceutical by 114.5% during the 4th quarter. AQR Capital Management LLC now owns 1,283,599 shares of the biotechnology company's stock worth $84,371,000 after acquiring an additional 685,099 shares in the last quarter. 98.71% of the stock is currently owned by institutional investors.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.